Efficacy and safety of ibandronat tablets for treatment of postmenopausal osteoporosis
Objective. To study efficacy and safety of ibandronat, highly active nitric-containing bisphosphonat in 3-year treatment of pts with postmenopausal osteoporosis using different doses and schemes of treatment. Material and methods. The study was performed as a part of a multicenter double blind place...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2005-10-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/325 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective. To study efficacy and safety of ibandronat, highly active nitric-containing bisphosphonat in 3-year treatment of pts with postmenopausal osteoporosis using different doses and schemes of treatment. Material and methods. The study was performed as a part of a multicenter double blind placebo-controlled randomized clinical study (BONE study). 85 female aged 55 to 80 yeare with 5-year or longer duration of postmenopausal period having from one to four vertebral fractures and lumbar bone mineral density (BMD) from - 2,0 to -5,0 SD according to T-count were included. The pts were randomized onto three groups: 1 - placebo, 2 - ibandronat 2,5 mg daily, 3 - ibandronat 20 mg every other day during the 24 days (12 doses) every 3 months. Results. After 3 years of treatment pts of group 2 and 3 showed significant increase of lumbar, femoral neck and total femoral BMD (5,9% and 5,8%, p<0,01, 2,0% and 1,9%, 3,3%(p<0,01 and 2,2% respectively). Ibandronat was well tolerated and its adverse events of were comparable with placebo. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |